This article raises some interesting points about the lack of oversight and when it’s appropriate to invoke the so-called “march-in” provision.
http://www.ipwatchdog.com/2016/01/21/bayh-dole-under-march-in-assault-can-it-hold-out/id=65118/.
This article raises some interesting points about the lack of oversight and when it’s appropriate to invoke the so-called “march-in” provision.
http://www.ipwatchdog.com/2016/01/21/bayh-dole-under-march-in-assault-can-it-hold-out/id=65118/.
I am not a patent or Bah-Dole expert, but I think that forcing drug companies to lower prices because they received federal grant money could be disastrous. Immediately it may lower prices, but it kills the incentives to produce new drugs. Marching in in this context could cause more harm than good.